Global Parkinson’s Disease Therapeutics Market is Expanding at CAGR of 5.6% from 2018 to 2026

According to the latest market report published by Acute Market Reports “Parkinson’s Disease Therapeutics Market – Growth, Future Prospects and Competitive Analysis, 2018 – 2026” the global Parkinson’s disease therapeutics market, was valued at US$ 2.41 Bn in 2017, and is expected to reach US$ 3.95 Bn by 2026 expanding at a CAGR of 5.6% from 2018 to 2026.

Browse the full report Parkinson’s Disease Therapeutics Market – Growth, Future Prospects and Competitive Analysis, 2018 – 2026 report at

Market Insights:

Parkinson’s disease is a type of progressive movement disorder, characterized by muscle rigidity, and tremors. The global Parkinson’s disease therapeutics market will grow significantly over the forecast period, majorly due to presence of late stage pipeline drugs such as APL-130277, Accordion Pill, P2B-001, ND0612H etc. and rising incidence of the disease. For the purpose of the study, the global Parkinson’s disease therapeutics market is categorized on the basis of drug class such as dopamine agonists, levodopa/carbidopa, anticholinergic drugs, monoamine oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors and adenosine A2 receptor antagonist. Levodopa coupled with carbidopa remains the standard treatment of Parkinson disease which shows fewer advarese effect in short-term use. Dopamine agonists are widely accepted for treatment of PD used as alone or in combination with levodopa/carbidopa. 

At present, North America leads the global PD therapeutics market owning to larger patient pool, advantage of early diagnosis, developed healthcare infrastructure and increase in prevalence of PD. It is predicted that PD therapeutics market in Asia Pacific will demonstrate lucrative growth over the forecast period because of rising prevalence of PD and improving healthcare infrastructure with developing economic condition.

Market Competition Assessment:  

It is observed that, companies such as Abbvie, Inc., Biogen, Inc., Boehringer Ingelheim GmbH, F. Hoffman-La Roche, GlaxoSmithKline Plc., H. Lundbeck A/S, Impax Labs, Inc., Newron Pharmaceuticals SpA, Novartis AG, Orion Corporation, Teva Pharmaceutical Industries Ltd., UCB S.A. etc. are key players involved in R&D and manufacturing of PD therapeutics market.


Key questions answered in this report

  • What are the current market trends and dynamics in the parkinsons disease therapeutics market and valuable opportunities for emerging players?
  • Estimated forecast and market projections up to 2029
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which is the largest regional market for parkinsons disease therapeutics?
  • What is the market trend and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • The worldwide market value of the parkinsons disease therapeutics market in 2019 and 2020
  • Which are the key trends driving the global parkinsons disease therapeutics market growth?
  • Who are the leading service providers in the parkinsons disease therapeutics market worldwide?

About Acute Market Reports

Acute Market Reports is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.

Contact Info.:-

Address: 90 Church St, FL 1 #3514,
New York, NY 10008
United States
Email: [email protected]
Toll Free(US/CANADA): +1-855-455-8662

Leave a Reply

Your email address will not be published. Required fields are marked *